Scottish Medicines Consortium

Showing 15 posts of 16 posts found.

nhs_sign_8

Scottish Medicines Consortium approves new drugs in multiple sclerosis, ulcerative colitis and diabetes

April 15, 2020
Research and Development, Sales and Marketing Biogen, Fambyra, Janssen, NHS, Rimzoic, Sandoz, Sanofi, Scotland, Scottish Medicines Consortium, Stelara, Suliqua, pharma

Medical regulation must still continue even in a global pandemic, and the Scottish Medicines Consortium, (SMC) has ploughed on with …

Shionogi’s Mulpleo recommended for NHS use across England, Wales and Scotland for chronic liver disease

December 12, 2019
Sales and Marketing England, Mulpleo, NICE, Scotland, Scottish Medicines Consortium, Shionogi, Wales

Both the regulators governing NHS use of medicines in England, Wales and Scotland – the National Institute for Health and …

gilead-sciences

Gilead’s CAR-T therapy Yescarta now available via NHS Scotland for two forms of B-cell lymphoma

October 8, 2019
Manufacturing and Production, Sales and Marketing CAR T, CAR-T, NHS, Scotland, Scottish Medicines Consortium, pharma

News has broken that the Scottish Medicines Consortium (SMC) has chosen to approve the use of Gilead’s chimeric antigen receptor …

merckwindow_web

Scotland approves first-line NHS use of MSD’s Keytruda combo for advanced non-small cell lung cancer

October 7, 2019
Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, keytruda, lung cancer, pharma

The Scottish Medicines Consortium (SMC) has announced its decision to accept MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) in combination with pemetrexed …

Scottish NHS patients to access Pfizer’s Ibrance combo in HR+/HER- breast cancer following SMC recommendation

July 11, 2019
Sales and Marketing Cancer, Scotland, Scottish Medicines Consortium, breast cancer, ibrance, pharma

Female NHS patients in Scotland will soon be able to access Pfizer’s cyclin-dependent kinase (CDK) 4/6 inhibitor Ibrance (palbociclib) after …

merck-keytruda

MSD’s Keytruda recommended on NHS in Scotland for Stage 3 melanoma

May 14, 2019
Manufacturing and Production, Sales and Marketing Cancer, MSD, Scotland, Scottish Medicines Consortium, keytruda, melanoma, pharma

MSD has revealed that Keytruda (pembrolizumab) will be made available to NHS Scotland patients after the Scottish Medicines Consortium (SMC) …

Eisai and MSD’s Lenvima recommended for NHS Scotland in advanced or unresectable liver cancer

April 8, 2019
Manufacturing and Production, Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, liver cancer, pharma

Patients in Scotland with with advanced or unresectable hepatocellular carcinoma (HCC) will now be able to access Eisai and MSD’s …

3922609891_dced293244_z

Rare lung cancer drug approved in Scotland

August 14, 2018
Manufacturing and Production Cancer, SMC, Scotland, Scottish Medicines Consortium, approval, lung cancer

The Scottish Medicines Consortium has approved Roche’s cancer drug alectinib for the treatment of patients with untreated advanced non-small-cell lung …

bms

SMC reverses decision on Opdivo in advanced skin cancer

August 8, 2016
Manufacturing and Production, Research and Development SMC, Scottish Medicines Consortium, melanoma, opdivo, skin cancer

The Scottish Medicines Consortium (SMC) has reversed an earlier decision for Bristol-Myers Squibb’s Opdivo (nivolumab) and has now approved recommended …

Scottish regulators back BMS’ Opdivo for lung cancer

July 13, 2016
Research and Development, Sales and Marketing Bristol-Myers Sqibb, NICE, Scottish Medicines Consortium, lung cancer, opdivo, regulation

Bristol-Myers Squibb (NYSE: BMY) said the Scottish Medicines Consortium (SMC) has recommended cancer immunotherapy Opdivo (nivolumab) to treat advanced squamous …

Jinarc

SMC approves first ever treatment for genetic kidney disease

January 12, 2016
Sales and Marketing Otsuka, SMC, Scottish Medicines Consortium, jinarc, kidney disease, tolvaptan

The Scottish Medicines Consortium (SMC) has approved Otsuka’s Jinarc for the treatment of the genetic kidney disease autosomal dominant polycystic …

Scotland flag

Cancer and MS drugs approved in Scotland

December 9, 2015
Sales and Marketing Celgene, Copaxone, Novartis, SMC, Scottish Medicines Consortium, Tevaq, ceritinib, glatiramer acetate, lenalidomide, lung cancer, multiple myeloma, multiple sclerosis, revlimis, zykadia

The Scottish Medicines Consortium (SMC) has approved three new treatments for lung cancer, multiple sclerosis and multiple myeloma, from Novartis, …

Scotland flag

Three new drugs approved for use in Scotland

November 12, 2015
Sales and Marketing Scottish Medicines Consortium

The Scottish Medicines Consortium (SMC) has given the go-ahead for the use of several drugs on the NHS in Scotland. …

zytiga

New cancer medicines approved in Scotland, available via NHS

October 12, 2015
Sales and Marketing Scottish Medicines Consortium, Zytiga, abiraterone acetate, prostate cancer

The Scottish Medicines Consortium (SMC) has today recommended Janssen’s Zytiga (abiraterone acetate) for use before chemotherapy in men with advanced …

NHS image

Scottish Medicines Consortium approves seven drugs

May 12, 2015
Sales and Marketing NHS, SMC, Scottish Medicines Consortium

The Scottish Medicines Consortium has accepted seven new medicines and indications for use on the NHS in Scotland. Two of …

Latest content